Royalty Pharma plc Research And Development Expense

Quick Answer

Royalty Pharma plc reported Research And Development Expense of $452.00 million for the year ending 2025.

  • Royalty Pharma plc showed an increase of +22,500.0% in Research And Development Expense from 2024 to 2025.
  • This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Royalty Pharma plc's Research And Development Expense has grown by 15.1%.
  • Historical annual values: Fiscal year 2025: $452.00 million | Fiscal year 2024: $2.00 million | Fiscal year 2023: $52.00 million | Fiscal year 2022: $177.11 million | Fiscal year 2021: $200.08 million | Fiscal year 2020: $26.29 million | Fiscal year 2019: $83.04 million | Fiscal year 2018: $392.61 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: